Definitive Contract HT942726CE011

The Defense Health Agency (DHA) awarded a Small Business Innovation Research (SBIR) Phase I contract to Grapheno, LLC for $249,978.59 to develop HaloVax, a clay nanotube-based vaccine delivery system designed to enable sustained release of an HIV vaccine through transdermal patches. This medical research and development contract, designated as a Total Small Business set-aside, represents the DHA's investment in innovative therapeutic delivery mechanisms that could advance HIV prevention...

The Defense Health Agency awarded a $3.93 million firm fixed-price definitive contract to Hexamer Therapeutics Inc. on September 29, 2023, for the development of a peptide-based, self-assembling molecular carrier scaffold vaccine platform designed for rapid deployment during infectious disease pandemics. The contract, which extends through March 31, 2027, will be performed at Hexamer's facility in Pullman, Washington. This award was issued under a Broad Agency Announcement solicitation from...

<p>This is a $149,710.00 firm fixed-price purchase order awarded by the Defense Logistics Agency Headquarters to Graphenix Development, Inc., a self-certified small disadvantaged business and manufacturer of goods. The contract is for a 12-month base period of performance under the SBIR (Small Business Innovation Research) Phase I program. The place of performance is Fort Belvoir, Virginia. The award was made on May 27, 2021, with a completion date of May 26, 2022.</p>

This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...

This is a $600,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to develop an effective human immunodeficiency virus (HIV) vaccine using engineered nanoparticles loaded with messenger RNA (mRNA) targeted to antigen presenting cells. This contract is part of the Small Business Innovation Research (SBIR)...

This is a federal contract award to Glaxosmithkline, LLC, a pharmaceutical company, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $1,937,251.00, is for the design and development of preventative HIV vaccines. The contract has an ultimate completion date of April 30, 2018 and was awarded on October 31, 2015. The contract is a definitive contract with a cost no fee pricing type and does...

This is a $1,298,431.22 firm fixed price contract awarded by the Defense Health Agency (DHA) to Solaris Vaccines, Inc., a small business located in Fort Collins, CO. The contract is for Phase II of the Small Business Innovation Research (SBIR) program and is for the development of a &quot;VacciraRptor: High-Throughput, Continuous Flow-Through System for Psoralen-UVA Inactivation.&quot; The contract has a performance period through November 1, 2027. This award is for a specific research and...

This is a $1,099,933.21 firm-fixed-price contract awarded by the U.S. Army Medical Command (MEDCOM) to Molecular Rebar Design LLC, a small business based in Austin, Texas. The contract is for a Phase II Small Business Innovation Research (SBIR) project titled &quot;Molecular Rebar Design's Discrete Multiwalled Carbon Nanotube HIV Therapy Technology.&quot; The contract aims to further develop a breakthrough modified carbon nanotube technology called Molecular Rebar for potential use in an HIV...

This is a $299,999.00 Firm Fixed Price Definitive Contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Luna Innovations Incorporated, a small business manufacturer, for the CNT-VECTORED DELIVERY OF MRNA FOR HIV-VACCINES research project under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the development and delivery of products and services related to this...

The National Institute of Allergy and Infectious Diseases issued a delivery order to Duke University on August 31, 2024, with a ceiling value of $5.885 million, for feasibility development of a liposome/LNP displaying an HIV Env trimer protein and containing/incorporating mRNA, and for preclinical and translational vaccine development support for HIV and other candidate agents. The order is issued under the parent indefinite delivery contract titled &quot;Preclinical and Translational Vaccine...